Speaker
Lisa Flaifel
VICE PRESIDENT, HEAD NEW BUSINESS DEVELOPMENT AND RADIOLOGY, BAYER PHARMACEUTICALS, BAYER AG
Lisa Flaifel is Vice President and Head of New Business Development and Radiology (NBD/RAD) within the Pharmaceuticals Business Development & Licensing and Open Innovation (BD&L/OI) function at Bayer. Lisa’s career embodies advancements through positions of progressive accountability in strategic marketing, sales, commercial leadership, and business development.
The NBD/RAD team serve as strategic partners in driving deal excellence, enhancing both valuation and commercial assessment expertise. Working across multiple therapeutic areas internally and externally, Lisa and her team constantly re-evaluate and evolve Bayer Pharmaceuticals’ approach to partnering.
She and her team are also responsible for the successful execution of the Radiology BD&L/OI strategy, with a focus on deals in platform and digital solutions aligned to the Radiology vision of being the solution provider.
Lisa joined Berlex/Bayer in 1998 and has directly worked on over 25 brands in various life cycle stages in Women’s Health, Radiology, and Cardiovascular/Cardiorenal Therapy Areas. She is known to be a dynamic and action-oriented leader, with a proven track record in building teams and achieving results in the healthcare industry. She is a collaborative and a strategic cross-functional partner, who drives solutions to complex business problems.
As part of her leadership journey, Lisa learned the value of creating teams where people feel safe. She is passionate about Inclusion and Diversity at Bayer and represents BD&L/OI within the global I&D Council.
Lisa serves on the board of directors for the ALS (Amyotrophic Lateral Sclerosis) Society of Canada. Both her father and brother-in-law were afflicted with ALS and succumbed to the disease in the late 1990’s.
The NBD/RAD team serve as strategic partners in driving deal excellence, enhancing both valuation and commercial assessment expertise. Working across multiple therapeutic areas internally and externally, Lisa and her team constantly re-evaluate and evolve Bayer Pharmaceuticals’ approach to partnering.
She and her team are also responsible for the successful execution of the Radiology BD&L/OI strategy, with a focus on deals in platform and digital solutions aligned to the Radiology vision of being the solution provider.
Lisa joined Berlex/Bayer in 1998 and has directly worked on over 25 brands in various life cycle stages in Women’s Health, Radiology, and Cardiovascular/Cardiorenal Therapy Areas. She is known to be a dynamic and action-oriented leader, with a proven track record in building teams and achieving results in the healthcare industry. She is a collaborative and a strategic cross-functional partner, who drives solutions to complex business problems.
As part of her leadership journey, Lisa learned the value of creating teams where people feel safe. She is passionate about Inclusion and Diversity at Bayer and represents BD&L/OI within the global I&D Council.
Lisa serves on the board of directors for the ALS (Amyotrophic Lateral Sclerosis) Society of Canada. Both her father and brother-in-law were afflicted with ALS and succumbed to the disease in the late 1990’s.
Speaking In
4:00 PM - 4:45 PM (EST)
Tuesday, February 7
Despite softening valuations among public biotechs and a major tightening of post-series B private…
South Broadway Ballroom
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
